المؤلفون: María Auxiliadora Dea-Ayuela, Lindsay Smith, Aikaterini Lalatsa, Francisco Bolás-Fernández, Dolores R. Serrano, Marion Mauger

المساهمون: UCH. Departamento de Farmacia, Producción Científica UCH 2018

المصدر: CEU Repositorio Institucional
Fundación Universitaria San Pablo CEU (FUSPCEU)
Smith, L, Serrano Lopez, D R, Mauger, M, Bolas-Fernandez, F, Dea Ayuela, M-A & Lalatsa, K 2018, ' Orally bioavailable and effective buparvaquone lipid based nanomedicines for visceral leishmaniasis ', Molecular Pharmaceutics, vol. 15, no. 7, pp. 2570-2583 . https://doi.org/10.1021/acs.molpharmaceut.8b00097

مصطلحات موضوعية: Male, Enfermedades parasitarias - Tratamiento, Pharmaceutical Science, Administration, Oral, 02 engineering and technology, Pharmacology, 030226 pharmacology & pharmacy, Mice, 0302 clinical medicine, Drug Stability, Drug Discovery, visceral leishmaniasis, Leishmania infantum, media_common, Drug Carriers, Mice, Inbred BALB C, Chemistry, Drugs - Administration, 021001 nanoscience & nanotechnology, oral delivery, solid nanomedicines, Lipids, Buparvaquone, self-nanoemulsifying drug delivery systems (SNEDDS), Treatment Outcome, Drug delivery, Molecular Medicine, Leishmaniasis, Visceral, Emulsions, 0210 nano-technology, neglected parasitic diseases, medicine.drug, Drug, Leishmaniasis - Farmacoterapia, Antiparasitic, medicine.drug_class, media_common.quotation_subject, Drug Compounding, Antiprotozoal Agents, Parasitic diseases - Treatment, Biological Availability, Medicamentos - Administración, RS, Cell Line, Excipients, 03 medical and health sciences, buparvaquone, medicine, Animals, Humans, Miltefosine, medicine.disease, In vitro, Communicable diseases - Treatment, Bioavailability, Disease Models, Animal, Drug Liberation, Visceral leishmaniasis, Enfermedades infecciosas - Tratamiento, Solubility, Feasibility Studies, Nanoparticles, Leishmaniasis - Chemotherapy, Naphthoquinones

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a483df47a232b6385c2635bfad2b8d8f
https://doi.org/10.1021/acs.molpharmaceut.8b00097